What antiplatelet therapy is the mainstay for NSTE-ACS?
Aspirin is the mainstay of antiplatelet therapy for NSTE-ACS. Non enteric-coated, chewable aspirin (162 mg to 325 mg) should be given to all patients with NSTE- ACS without contraindications as soon as possible after presentation, and a maintenance dose of aspirin (81 mg/d to 325 mg/d) should be continued indefinitely. In patients with NSTE-ACS who are unable to take aspirin because of hypersensitivity or major gastrointestinal intolerance, a loading dose of clopidogrel followed by a daily maintenance dose should be administered. For patients with intermediate/high-risk features, a GP IIb/IIIa inhibitor, such as eptifibatide or tirofiban, may be considered as part of initial antiplatelet therapy. 